Clinical

Articles

Clinical activity of the combination of pertuzumab and trastuzumab in seen in patients with ERBB2/ERBB3 overexpressing uterine cancers. 

ERBB2/ERBB3+ Uterine Cancer Shows Disease Control With Combination of Pertuzumab and Trastuzumab

Results presented at part of the European Society for Medical Oncology Virtual Plenary show positive results of a phase 3 trial comparing cemiplimab with chemotherapy for previously treated cervical cancer. 

Cemiplimab Improves OS Versus Chemotherapy Across Histologic Subtypes in Recurrent Cervical Cancer

In the advanced treatment setting, an FDA decision has indicated that the combination of pembrolizumab and lenvatinib may soon be available for certain patients with endometrial tumors and renal cell carcinoma. 

Pembrolizumab Plus Lenvatinib Earns Priority Review in 2 Disease Indications

Videos

CancerNetwork® spoke with Ronnie Shapira-Frommer, MD, during the Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women’s Cancer about her thoughts on the effect of the conference content across multidisciplinary specialties.

Ronnie Shapira-Frommer, MD, Discusses Multidisciplinary Care to Treat Gynecologic Malignancies 

CancerNetwork® spoke with Ronnie Shapira-Frommer, MD, during the Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women’s Cancer about patients with vulvar cancer who were treated with pembrolizumab monotherapy.

Ronnie Shapira-Frommer, MD, on Next Steps for Exploring Pembrolizumab Monotherapy in Patients With Vulvar Squamous Cell Carcinoma 

CancerNetwork® spoke with Ronnie Shapira-Frommer, MD, during the Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women’s Cancer about patients with vulvar cancer who were responders to pembrolizumab monotherapy.

Ronnie Shapira-Frommer, MD, on Characteristics of Responders With Vulvar Squamous Cell Carcinoma Treated on the KEYNOTE-158 Trial 

CancerNetwork® spoke with Ronnie Shapira-Frommer, MD, during the Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women’s Cancer about a cohort of patients with vulvar cancer treated with pembrolizumab monotherapy.

Ronnie Shapira-Frommer, MD, on Results From the KEYNOTE-158 Trial in Patients With Vulvar Squamous Cell Carcinoma

CancerNetwork® spoke with Ronnie Shapira-Frommer, MD, during the Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women’s Cancer about data focusing on a cohort of patients with vulvar cancer treated with pembrolizumab monotherapy.

Ronnie Shapira-Frommer, MD, on the Rationale for the KEYNOTE-158 Trial in Patients With Vulvar Squamous Cell Carcinoma

Patients with heavily pretreated vulvar squamous cell carcinoma experienced responses with pembrolizumab monotherapy in a nonrandomized phase 2 trial, regardless of PD-L1 status. 


Pembrolizumab Induces Notable Response Rate in Patients With Pretreated Vulvar Squamous Cell Carcinoma

CancerNetwork® discussed updates in the treatment of gynecologic cancers with Ursula A. Matulonis, MD.

Gynecologic cancer | Topics